HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy

Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Hematological Oncology ◽

10.1002/hon.2897 ◽

2021 ◽

Author(s):

Olga Meltem Akay ◽

Murat Ozbalak ◽

Mustafa Pehlivan ◽

Birol Yildiz ◽

Ant Uzay ◽

...

Keyword(s):

Stem Cell ◽

Retrospective Study ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy

Poster: HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(21)01484-1 ◽

2021 ◽

Vol 21 ◽

pp. S236

Author(s):

Murat Ozbalak ◽

Olga Meltem Akay ◽

Mustafa Pehlivan ◽

Birol Yildiz ◽

Ant Uzay ◽

...

Keyword(s):

Stem Cell ◽

Retrospective Study ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy

Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation

Cancer ◽

10.1002/cncr.30818 ◽

2017 ◽

Vol 123 (19) ◽

pp. 3763-3771 ◽

Cited By ~ 11

Author(s):

Lucy Hui ◽

Gottfried von Keudell ◽

Rong Wang ◽

Amer M. Zeidan ◽

Steven D. Gore ◽

...

Keyword(s):

Stem Cell ◽

Cost Effectiveness ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma

Journal of Pediatric Hematology/Oncology ◽

10.1097/mph.0000000000001703 ◽

2019 ◽

Vol Publish Ahead of Print ◽

Author(s):

Karen S. Fernández ◽

Melissa Mavers ◽

Lianna J. Marks ◽

Rajni Agarwal

Keyword(s):

Stem Cell ◽

Children And Adolescents ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Early Relapse

Faculty Opinions recommendation of Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725403083.793507191 ◽

2015 ◽

Author(s):

Greg Bociek

Keyword(s):

Stem Cell ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Consolidation Therapy ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Risk Of Relapse

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Annals of Oncology ◽

10.1093/annonc/mdx791 ◽

2018 ◽

Vol 29 (3) ◽

pp. 724-730 ◽

Cited By ~ 11

Author(s):

A.F. Herrera ◽

J. Palmer ◽

P. Martin ◽

S. Armenian ◽

N.-C. Tsai ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Second Line ◽

Refractory Hodgkin Lymphoma

Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

Bone Marrow Transplantation ◽

10.1038/s41409-020-0935-0 ◽

2020 ◽

Vol 55 (12) ◽

pp. 2322-2325

Author(s):

Moussab Damlaj ◽

Khadega A. Abuelgasim ◽

Ayman Alhejazi ◽

Bader Alahmari ◽

Ahmed Alaskar ◽

...

Keyword(s):

Stem Cell ◽

High Risk ◽

Hematopoietic Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Brentuximab Vedotin ◽

Classical Hodgkin Lymphoma ◽

Hematopoietic Stem

P110 (0014) SUCCESSFUL TREATMENT OF HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION

HemaSphere ◽

10.1097/01.hs9.0000547957.90757.f2 ◽

2018 ◽

Vol 2 (S3) ◽

pp. 45 ◽

Cited By ~ 1

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Successful Treatment ◽

Brentuximab Vedotin

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

British Journal of Haematology ◽

10.1111/bjh.16201 ◽

2019 ◽

Vol 188 (4) ◽

pp. 540-549 ◽

Cited By ~ 4

Author(s):

Panayotis Kaloyannidis ◽

Mark Hertzberg ◽

Kate Webb ◽

Athanasios Zomas ◽

Rudolf Schrover ◽

...

Keyword(s):

Stem Cell ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Brentuximab Vedotin ◽

Refractory Hodgkin Lymphoma

High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma

Clinical and Experimental Medicine ◽

10.1007/s10238-011-0157-2 ◽

2011 ◽

Vol 12 (3) ◽

pp. 165-171 ◽

Cited By ~ 11

Author(s):

Franca Falzetti ◽

Mauro Di Ianni ◽

Stelvio Ballanti ◽

Giuseppe Iodice ◽

Antonia Reale ◽

...

Keyword(s):

Stem Cell ◽

High Risk ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Conditioning Regimen ◽

High Dose ◽

Non Hodgkin Lymphoma